First Horizon Advisors Inc. Has $145,000 Holdings in Stevanato Group S.p.A. (NYSE:STVN)

First Horizon Advisors Inc. raised its stake in shares of Stevanato Group S.p.A. (NYSE:STVN) by 14.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 5,311 shares of the company’s stock after purchasing an additional 657 shares during the period. First Horizon Advisors Inc.’s holdings in Stevanato Group were worth $145,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in STVN. Conestoga Capital Advisors LLC increased its stake in Stevanato Group by 0.5% in the 4th quarter. Conestoga Capital Advisors LLC now owns 4,557,278 shares of the company’s stock valued at $124,368,000 after buying an additional 23,190 shares during the last quarter. Copeland Capital Management LLC raised its position in shares of Stevanato Group by 18.6% in the fourth quarter. Copeland Capital Management LLC now owns 2,088,778 shares of the company’s stock valued at $57,003,000 after purchasing an additional 327,960 shares during the period. TimesSquare Capital Management LLC lifted its stake in shares of Stevanato Group by 64.2% during the 3rd quarter. TimesSquare Capital Management LLC now owns 2,032,361 shares of the company’s stock valued at $60,402,000 after buying an additional 794,391 shares in the last quarter. Sands Capital Management LLC boosted its holdings in Stevanato Group by 46.5% in the 3rd quarter. Sands Capital Management LLC now owns 1,854,880 shares of the company’s stock worth $55,127,000 after buying an additional 588,757 shares during the period. Finally, Riverbridge Partners LLC grew its stake in Stevanato Group by 78.1% in the 4th quarter. Riverbridge Partners LLC now owns 1,274,805 shares of the company’s stock valued at $34,789,000 after buying an additional 559,070 shares in the last quarter.

Stevanato Group Price Performance

STVN opened at €26.67 ($28.68) on Tuesday. The company has a fifty day moving average price of €29.63 and a 200-day moving average price of €29.13. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.06 and a current ratio of 1.50. Stevanato Group S.p.A. has a one year low of €23.00 ($24.73) and a one year high of €36.30 ($39.03).

Stevanato Group (NYSE:STVN) last released its quarterly earnings results on Thursday, March 7th. The company reported €0.18 ($0.19) EPS for the quarter, missing analysts’ consensus estimates of €0.19 ($0.20) by (€0.01) (($0.01)). The firm had revenue of €320.60 million for the quarter, compared to analysts’ expectations of €326.85 million. Stevanato Group had a net margin of 13.43% and a return on equity of 14.31%. The firm’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.19 earnings per share. Sell-side analysts anticipate that Stevanato Group S.p.A. will post 0.67 EPS for the current year.

Analysts Set New Price Targets

STVN has been the subject of a number of analyst reports. Stephens reaffirmed an “overweight” rating and issued a $38.00 price target on shares of Stevanato Group in a report on Monday, March 25th. BNP Paribas assumed coverage on Stevanato Group in a research note on Monday, April 22nd. They issued an “outperform” rating for the company. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $30.00 price target on shares of Stevanato Group in a research report on Monday, April 22nd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Stevanato Group currently has an average rating of “Moderate Buy” and an average price target of €34.29 ($36.87).

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.